Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Cancer
- cell therapy
- Therapeutic
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 298723
Products means any allogeneic Chimeric Antigen Receptor T-cell therapy in which cells are modified to knockdown one or more Targets by using shRNA, using Licensor Intellectual Property Rights pursuant to this Agreement, or any other product whose manufacture, use or sale would, in the absence of a license from Licensor, constitute direct, indirect, contributory or any other type of infringement of one or more claims of Licensor Intellectual Property Rights.
The patents include Micro-RNA scaffolds and non-naturally occuring micro-RNAs, and, Micro-RNA scaffolds, non-naturally occurring micro-RNAs, and methods for optimizing non-naturally occurring micro-RNAs.
A Phase 1 dose-escalation trial evaluating the safety and clinical activity of CYAD-02 is planned for early 2020 and will involve a preconditioning chemotherapy (CyFlu) in patients with relapse/refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).
IPSCIO Record ID: 362483
– to generate and test Chimeric Antigen Receptor T-Cell Products solely for the Development, Regulatory Approval and Commercialization of Products containing such Chimeric Antigen Receptor I-Cell Products;
– to Develop and Commercialize Products in the Field in the Territory, provided that such Products are not Out-of-Scope Products; and
– to Commercialize the Chimeric Antigen Receptor for Products.
Product means any pharmaceutical product containing a Chimeric Antigen Receptor I-Cell Product developed by Licensor under a Research Program for which the JSC determines to file an IND or under a research program for which Licensee has exercised the Licensor Program Option, or, any pharmaceutical product containing a Chimeric Antigen Receptor T-Cell Product developed by or on behalf of Licensee that is a derivative of or is otherwise developed from or based upon a Chimeric Antigen Receptor T-Cell Product described above.
Allogcneic Cell Therapy means a genomically engineered patient-nonspecific T-cell expressing a Chimeric Antigen Receptor for delivery to a patient developed under the Allogeneic Cell Therapy Research Program satisfying the Allogeneic Cell Therapy Criteria.
Chimeric Antigen Receptor T-Cell Product means a T-Cell having a Chimeric Antigen Receptor, or, a T-cell under switch control having a Chimeric Antigen Receptor and any Activator Ligands or Exclusive Activator Ligands that are administered to control such T-cells irrespective of whether such Activator Ligands or Exclusive Activator Ligands are packaged with and/or delivered with such T-cell directed to a Target, or, an Allogeneic Cell Therapy, or, the Allogeneic Cell Therapy under switch control having a Chimeric Antigen Receptor directed to a Target and any Activator Ligands or Exclusive Activator Ligands that are administered to control such Allogeneic Cell Therapy irrespective of whether such Activator Ligands or Exclusive Activator Ligands are packaged with and/or delivered with such Allogeneic Cell Therapy, or, any component sold as a kit, such as a device, delivery system or therapy scheme for the above to modify such T-cell including one or more polypeptides or nucleic acids encoding a CAR.
Licensor Platform Technology means Licensors platform of research tools and technology necessary for Licensor to perform its tasks directed towards the design, identification, culturing, and/or production of genetically modified cells consistent with this Agreement, including without limitation the technology embodied in the Licensor Materials and the Licensor Patents, and specifically including without limitation the following of Licensors platform areas and capabilities
(I) UltraVcctor,
(2) LEAP,
(3) DNA and RNA MOD engineering,
(4) protein engineering,
(5) transcription control chemistry,
(6) genome engineering,
(7) cell system engineering,
(8) Endometrial Regenerative Cells,
(9) the RheoSwitchE technology and RheoSwitch Therapeutic Systems, and
(10) MD Anderson CC Technologies.
IPSCIO Record ID: 26488
IPSCIO Record ID: 336301
This license shall continue in full force and effect, on a country-by-country and Licensed Product-by- Licensed Product basis, until the expiration of all of Licensee’s payment obligations hereunder, after which time Licensee shall retain a perpetual, irrevocable, sublicenseable, nonexclusive license to any Intellectual Property Rights licensed to Licensee pursuant to the terms of this Agreement during the Term, solely within the scope of the licenses granted to Licensee herein during the Term.
CAR means a chimeric antigen receptor.
CAR Product means a pharmaceutical or biologic product in any form or composition containing a CAR T-Cell.
CAR T-Cell means an engineered T-Cell that expresses one or more CARs that are directed against a particular Target.
Patents
US application #61 /765,585 – Chimeric Antigen Receptor and Methods of use thereof.
US application #62/276,725 – Conditionally Active Heterodimeric Polypeptides and methods of use thereof.
US application #62/212,999 – Modular Polypeptide Libraries and Methods of Making and Using Same.
“AML†means acute myeloid leukemia or acute myelogenous leukemia.
The Licensee will receive rights to develop and commercialize CAR-based product candidates containing Licensor's on/off switches†directed to certain targets that are associated with acute myeloid leukemia.
IPSCIO Record ID: 312594
In April 2020, the Court granted in part Licensor’s motion and entered a final judgment awarding royalties on Licensee’s sales of Yescarta* from December 13, 2019 through the expiration of the Patent in August 2024.
Yescarta is a trademark of Licensee. Yescarta, a CAR T cell therapy, involves (i) harvesting T cells from the patient’s blood, (ii) engineering T cells to express cancer-specific receptors, (iii) increasing the number of engineered T cells and (iv) infusing the functional cancer-specific T cells back into the patient.
